Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15728813 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukaemia Refractory
Intervention: Drug: Rituximab

Indicates status has not been verified in more than two years